GGrantIndex
Sort

16,300 grants matching fatty liver disease

Bariatric Surgery Research Consortium

$398,005
University Of Washington · U01 · FY2004 · DK

Quantitative characterization of the liver-pancreas axis in diabetes via multiparametric magnetic resonance elastography

$397,974
Meng Yin · Mayo Clinic Rochester · R01 · FY2023 · DK

Cardiac Dysfunction in the Met Syndrome: Cross-talk between IR and bAR Signaling

$397,938
Evan Dale Abel · University Of Iowa · R01 · FY2015 · HL

Regulation of mitochondrial metabolism by lysine acylation

$397,912
Eric S Goetzman · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · DK

Molecular Mechanisms of Adverse Metabolic Events by Asparaginase.

$397,803
Tracy G. Anthony · Rutgers, The State Univ Of N.J. · R01 · FY2012 · HD

Sleep Apnea and Dysregulation of Lipid Metabolism

$397,782
Vsevolod Y Polotsky · Johns Hopkins University · R01 · FY2014 · HL

Genetics of Type 2 Diabetes

$397,747
Swapan Kumar Das · Wake Forest University Health Sciences · R01 · FY2010 · DK

Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation

$397,624
Grace L Guo · Rutgers, The State Univ Of N.J. · R01 · FY2021 · GM

Investigating the involvement of small intestine in metformin's effect on hepatic lipid metabolism

$397,608
Xiaojing Liu · North Carolina State University Raleigh · R35 · FY2023 · GM

Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation

$397,590
Guangfu Li · University Of Connecticut Sch Of Med/Dnt · R01 · FY2024 · DK

Functions of BNIP3 in lipid metabolism in the liver and in hepatocellular carcinoma

$397,573
Kay F Macleod · University Of Chicago · R01 · FY2020 · CA

Functions of BNIP3 in lipid metabolism in the liver and in hepatocellular carcinoma

$397,573
Kay F Macleod · University Of Chicago · R01 · FY2017 · CA

Clincal Research Network in Non-Alcoholic Steatohepatitis (NASH CRN)

$397,566
Arthur J McCullough · Cleveland Clinic Lerner Com-Cwru · U01 · FY2013 · DK

Cytoskeletal Regulation Of Vesicle Transport In Liver

$397,500
Mark A. Mc Niven · Mayo Clinic Rochester · R56 · FY2022 · DK

Ketogenic oscillations and neurometabolic healthspan

$397,500
Peter A Crawford · University Of Minnesota · R01 · FY2020 · AG

Interplay Between Macrophages, Lipid Oxidation and the Nrf2/HO-1 Axis in the Cardiometabolic Toxicity Induced by Ultrafine Particles

$397,402
Jesus Antonio Araujo · University Of California Los Angeles · R01 · FY2022 · ES

Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH

$397,398
Fabio Cohen Tucci · Epigen Biosciences, Inc. · R43 · FY2021 · DK

Mechanistically based therapeutic strategies in murine primary biliary cholangitis

$397,389
Merrill E Gershwin · University Of California At Davis · R01 · FY2022 · DK

Fructose Metabolism as a Biomarker for Monitoring Hepatocellular Carcinoma

$397,258
Sui Seng Tee · University Of Maryland Baltimore · R21 · FY2020 · CA

ANGPTL8: function and mechanism of action

$397,255
Ren Zhang · Wayne State University · R01 · FY2017 · HL

CSN8 regulation of S1P-enriched extracellular vesicles to modulate NAFLD by gut-liver axis

$397,195
Zhong-Bin Deng · University Of Louisville · R01 · FY2021 · DK

Novel Liver Signaling Pathways Controlling Adiposity

$397,165
Terry D Hinds · University Of Kentucky · R01 · FY2024 · DK

University of Pittsburgh MACS/WIHS CCS- Supplement Funds from NHLBI

$397,060
Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · U01 · FY2019 · HL

Oxidation-specific nanoparticles for imaging atherosclerosis

$396,920
Sotirios Tsimikas · University Of California, San Diego · R01 · FY2015 · HL

The novel role of FGF21 in mediating sex-dependent responses to dietary macronutrients

$396,915
Karen Ryan · University Of California At Davis · R01 · FY2019 · DK